Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 8, 2011

Washington Should Help Smaller Biotechs Gain International IP Protection According to Poll

  • The federal government should provide money to help small businesses establish international IP protection, poll voters agreed by nearly two-to-one. Of respondents 62.5% agreed with industry advocates looking to Washington to help smaller companies protect their intellectual property for treatments and technologies. The rest said that the government should not get involved.

    How to help is under study by the US Patent and Trademark Office, which is compiling recommendations for helping smaller businesses in and outside the life sciences gain international patent protection. Smaller biotech businesses, often cash-strapped and limited to the knowledge of their management and investors, have long struggled to protect IP in a global industry governed by patent laws and agencies that are still mostly national in scope.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »